Henry Schein 2006 Annual Report Download - page 7

Download and view the complete annual report

Please find page 7 of the 2006 Henry Schein annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 28

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28

FINANCIAL HIGHLIGHTS
5
75 YEARS OF SUCCESS
NOTES:
Operating Margin and Earnings from Continuing Operations Per Diluted Share have been adjusted to exclude certain one-time items. Refer to Non-GAAP Disclosures on page 21.
Additionally, refer to our annual consolidated financial statements for a complete presentation of our Consolidated Statements of Cash Flows.
(1) During 2004, we recorded a non-recurring $13.2 million pre-tax ($8.4 million post-tax) charge related to the Fluvirin®contract with Chiron Corporation.
The effect that this charge had on earnings per share for the year ended December 25, 2004 was ($0.10). Excluding this charge, our earnings per diluted share for 2004 was $1.39.
(2) Return on Committed Capital represents operating income over average committed capital (committed capital equals inventory plus trade accounts receivables
and net property, plant and equipment less trade accounts payables.)
(3) Adjusted to reflect the effect of our adoption, on January 1, 2006, of FAS 123(R) using the modified retrospective application.
NET SALES
From Continuing Operations
($ in millions)
OPERATING MARGIN
From Continuing Operations
EARNINGS PER
DILUTED SHARE
From Continuing Operations
RETURN ON
COMMITTED CAPITAL
OPERATING CASH FLOW
($ in millions)
(2)
(3)
(3) (3)
See the Notes below for
discussion of Non-GAAP Disclosures
See the Notes below for
discussion of Non-GAAP Disclosures